Adc Therapeutics SA [NYSE: ADCT] gained 1.79% or 0.05 points to close at $2.85 with a heavy trading volume of 323648 shares.
It opened the trading session at $2.83, the shares rose to $2.85 and dropped to $2.735, the range by which the price of stock traded the whole day. The daily chart for ADCT points out that the company has recorded 50.00% gains over the past six months.
If we look at the average trading volume of 681.22K shares, ADCT reached to a volume of 323648 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Adc Therapeutics SA [ADCT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ADCT shares is $8.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ADCT stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Stephens have made an estimate for Adc Therapeutics SA shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on November 08, 2024. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Overweight. The new note on the price target was released on May 30, 2024, representing the official price target for Adc Therapeutics SA stock. Previously, the target price had yet another raise to $11, while Guggenheim analysts kept a Buy rating on ADCT stock.
Trading performance analysis for ADCT stock
Adc Therapeutics SA [ADCT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.56. With this latest performance, ADCT shares dropped by -20.61% in over the last four-week period, additionally plugging by 50.00% over the last 6 months – not to mention a rise of 43.22% in the past year of trading.
Adc Therapeutics SA [ADCT]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Adc Therapeutics SA [ADCT] shares currently have an operating margin of -165.54% and a Gross Margin at 88.48%. Adc Therapeutics SA’s Net Margin is presently recorded at -197.64%.
Return on Equity for this stock declined to -51.62%, with Return on Assets sitting at -51.62%.
Adc Therapeutics SA [ADCT]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ADCT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Adc Therapeutics SA go to 16.36%.
An analysis of Institutional ownership at Adc Therapeutics SA [ADCT]
There are presently around $67.58%, or 86.19% of ADCT stock, in the hands of institutional investors. The top three institutional holders of ADCT stocks are: REDMILE GROUP, LLC with ownership of 15.27 million shares, which is approximately 15.9568%. PROSIGHT MANAGEMENT, LP, holding 9.57 million shares of the stock with an approximate value of $$30.24 million in ADCT stocks shares; and PROSIGHT MANAGEMENT, LP, currently with $$13.64 million in ADCT stock with ownership which is approximately 4.5112%.
